Congressional Push to Exclude Chinese Clinical Data Lacks Evidence Base, Threatens Gene Therapy Pipelines

Lawmakers Demand FDA Action on China Clinical Trial Deaths

Two U.S. Congress members, Reps. John Moolenaar (R-MI) and Ben Cline (R-VA), have formally urged Acting FDA Commissioner Kyle Diamantas to implement new policies regarding clinical data from China. This call to action follows three reported patient deaths in separate gene therapy clinical trials conducted in China. The lawmakers specifically requested that the FDA reject clinical data from China unless the trial site has undergone a recent FDA audit, and to conduct a wide-ranging review of products already approved in the U.S. based on Chinese clinical results, citing significant risks to American patients.

• Congressional Call for Stricter FDA Oversight: U.S. Representatives John Moolenaar and Ben Cline have penned a letter to Acting FDA Commissioner Kyle Diamantas, demanding new policies for clinical data originating from China. Their primary requests include the rejection of Chinese clinical trial data unless the site has undergone a recent FDA audit and a comprehensive review of all U.S.-approved products that relied on Chinese clinical results, emphasizing the inherent risks to patient safety.
• Three Fatalities Fueling Legislative Concern: The impetus for this congressional intervention stems from three recent patient deaths in China-based gene therapy trials. These include a young boy with Duchenne muscular dystrophy who died after receiving HuidaGene’s investigational CRISPR-based therapy, HG302; a patient with systemic sclerosis in a RiboX Therapeutics experimental in vivo CAR T cell therapy trial; and a six-year-old girl with Snijders Blok-Campeau syndrome who succumbed to a severe immune reaction from a brain-directed gene-editing therapy.
• Broader Implications for Global Clinical Research: The incidents underscore growing U.S. scrutiny of China's biotech sector, touching on national security and innovation concerns. The press release highlights that China has surpassed the U.S. in annual registered clinical trials and cancer drug approvals, with early-phase trials in China often being faster and more cost-effective. This trend of offshoring research, however, is now being critically re-evaluated in light of the reported patient fatalities and calls for enhanced regulatory safeguards.

Lawmakers Demand FDA Scrutiny After Gene Therapy Safety Signals

Clinical safety data from DMD trials reveal distinct adverse event profiles depending on therapeutic modality, with AAV-based gene therapies carrying the most serious risk signals — including immune-mediated toxicities that have drawn significant regulatory and legislative attention.

• Mild-to-moderate infusion-related events are common across AAV platforms. In the rAAVrh74.MHCK7.micro-dystrophin trial, all 53 reported adverse events were mild (62%) or moderate (38%), with vomiting as the most frequent treatment-related event (50% of 18 events) and transient γ-glutamyltransferase elevations managed with corticosteroids.

• Fordadistrogene movaparvovec demonstrated a broader systemic AE burden. In the ambulatory cohort, the most commonly reported treatment-emergent adverse events included vomiting (n=15), nausea (n=10), thrombocytopenia (n=9), pyrexia (n=9), decreased appetite (n=8), fatigue (n=7), and headache (n=7); three serious treatment-related events — dehydration, acute kidney injury, and thrombocytopenia — all resolved within 15 days.

• Severe and fatal outcomes have been documented in nonambulatory patients. The nonambulatory cohort in the fordadistrogene movaparvovec program experienced two severe treatment-related adverse events: hemolytic uremic syndrome and a fatal cardiogenic shock episode.

• Immune-mediated toxicities represent the most clinically significant safety signal across high-dose AAV therapies. Delandistrogene moxeparvovec has been associated with myositis, myocarditis, thrombocytopenia, and liver toxicity; one death was reported in a patient treated outside of a clinical trial. More broadly, two deaths following high-dose AAV gene therapy in DMD have been attributed to AAV-mediated immune responses, with complement activation and hepatotoxicity identified as key mechanistic drivers.

• Antisense oligonucleotides carry a comparatively favorable safety profile. Long-term real-world data from approved exon-skipping ASOs — eteplirsen, golodirsen, viltolarsen, and casimersen — suggest broad tolerability, though next-generation ASO compounds with improved molecular efficacy may not share the same established safety track record as first-generation agents.

Addressing Unmet Needs in DMD: The Drive for Novel Therapies

Despite meaningful therapeutic advances in Duchenne muscular dystrophy (DMD), existing treatment modalities continue to face significant clinical, technical, and biological constraints that limit their real-world impact. No current therapy addresses all dimensions of the disease, and the gap between molecular intervention and durable functional benefit remains substantial.

• Gene therapy efficacy and safety remain unconfirmed long-term. Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, has shown transgene expression and early functional signals, but its long-term durability and safety profile are yet to be established. Immune-mediated toxicities — including myositis, myocarditis, and hepatotoxicity — necessitate rigorous immunoprophylaxis and post-treatment surveillance. Pre-existing anti-AAV immunity further restricts eligibility, excluding a meaningful patient subset from systemic gene transfer approaches altogether.

• Technical barriers constrain next-generation gene therapy development. Vector size limitations restrict the payload capacity of current AAV-based systems, driving exploratory work into dual/triple AAV configurations, non-viral delivery platforms, and capsid and promoter engineering to improve muscle tropism. Desensitization protocols are also under investigation to broaden patient eligibility.

• Antisense oligonucleotide therapies carry unresolved efficacy and delivery challenges. Eteplirsen, the most prominent exon-skipping therapy in clinical use, remains clinically controversial, with its demonstrated therapeutic effect considered insufficient by a substantial portion of the scientific community. Beyond efficacy questions, systemic delivery and tissue penetrance of antisense oligonucleotides continue to pose practical limitations.

• Chronic corticosteroid use is associated with significant iatrogenic morbidity. Prednisone at 0.75 mg/kg/day — the longstanding standard of care — carries well-documented risks including weight gain, cushingoid features, and hirsutism. Deflazacort, while associated with less weight gain, carries a comparatively elevated cataract risk. Mechanistically, chronic glucocorticoid exposure drives gut dysbiosis, inducing a pro-inflammatory phenotype and compromised gut barrier integrity that may underlie several systemic side effects. Growth stunting observed in corticosteroid-treated patients — but not in vamorolone-treated trial participants — further underscores the need for safer alternatives.

• Cardiac management remains non-targeted and increasingly critical. The specific mechanisms driving heart failure in DMD are incompletely understood, limiting therapeutic precision. Current cardiac care relies on standard dilated cardiomyopathy (DCM) approaches — principally ACE inhibitors and β-adrenoceptor antagonists — rather than disease-specific interventions. With improving survival, the clinical burden of cardiomyopathy is escalating: virtually all DMD patients over 18 years of age exhibit signs of cardiac involvement, and heart failure and sudden death continue to significantly impact both survival and quality of life.

Gene Therapy Data from China Under the Microscope

The burgeoning field of gene therapy holds immense promise for addressing previously intractable diseases, yet its inherent complexities demand the highest standards of clinical rigor and patient safety. Recent calls from U.S. lawmakers for the FDA to impose stricter oversight on clinical data originating from China, specifically citing patient deaths in gene therapy trials, bring this critical balance into sharp focus. This development signals a potential inflection point for how global clinical research is conducted and regulated, particularly concerning novel therapeutic modalities.

Existing evidence indicates that while gene therapies generally exhibit an acceptable safety profile for severe human diseases, they are not without risks. Studies have shown that serious adverse events and even deaths can occur in gene therapy trials, though often not directly related to the active therapy itself. This underscores the necessity for meticulous long-term safety follow-up, a process that can be challenging due to factors like patient loss to follow-up, which can obscure a complete safety picture. The lawmakers' intervention suggests a concern that the current mechanisms for evaluating foreign clinical data, particularly from regions where clinical audit standards may vary, might not be sufficiently robust to mitigate these inherent risks.

For pharmaceutical companies, the strategic implications are clear and substantial. There will be an undeniable increase in the burden of ensuring that all foreign clinical trial sites, especially those in China, not only adhere to Good Clinical Practices (GCP) but are also prepared for and undergo recent FDA audits. This heightened scrutiny could lead to significant delays in drug development timelines and escalate costs, as sponsors invest more in direct oversight and quality assurance. Furthermore, companies with products already approved based on Chinese clinical data may face the risk of re-evaluation of their regulatory dossiers, potentially leading to post-market requirements or, in extreme scenarios, market withdrawal if data integrity concerns are substantiated. This evolving regulatory landscape emphasizes that while global collaboration in clinical research is vital, the integrity and verifiability of data remain paramount for patient safety and regulatory confidence.